Rewiring Autoimmune Care: The Bioelectronic Disruption of RA

ALBUQUERQUE, NM – November 03, 2026 — Rheumatoid arthritis has long been the exclusive domain of rheumatologists and an escalating arsenal of immunosuppressive pharmaceuticals. But inside an operating room at the University of New Mexico (UNM) Hospital this week, the latest intervention for severe joint inflammation was not a biologic infusion or a synthetic targeted drug. It was a surgical procedure performed by a neurosurgeon.

SetPoint Medical, a California-based medical technology company, announced today the completion of the first commercial SetPoint System procedures in New Mexico. The milestone is part of a calculated, state-by-state commercial rollout of the first and only U.S. Food and Drug Administration (FDA)-approved neuroimmune modulation therapy for adults living with moderate-to-severe rheumatoid arthritis (RA).

For the estimated 1.5 million Americans living with RA, the standard of care involves a treadmill of disease-modifying antirheumatic drugs (DMARDs). Yet, a significant subset of patients either fail to achieve remission, lose their response over time, or suffer intolerable side effects from systemic immunosuppression. SetPoint's device offers a radical pivot: treating an immune system malfunction with a hardware solution.

As the bioelectronic medicine sector moves from theoretical promise to commercial execution, the rollout in New Mexico offers a real-world look at how cross-specialty collaboration and novel reimbursement models are attempting to disrupt a $30 billion autoimmune drug market.

The Hardware of Healing

The SetPoint System does not rely on chemical compounds to suppress the immune system. Instead, it leverages the body's own neural circuitry—specifically, the inflammatory reflex of the vagus nerve.

Surgically implanted on the left vagus nerve in the neck, the miniaturized neurostimulator delivers targeted electrical impulses designed to activate innate anti-inflammatory pathways, effectively turning down the immune system's attack on healthy joint tissue. The patient experience is remarkably low-friction: the implant is charged wirelessly at home using a wearable neck collar for just a few minutes each week, and the active stimulation lasts for only one minute per day.

This is not a concept in its infancy; it is a commercially validated therapy backed by rigorous clinical data. The FDA granted Premarket Approval (PMA) in July 2025, supported by the pivotal RESET-RA clinical trial. Published earlier this year in Nature Medicine, the trial data demonstrated that 35.2% of patients receiving active stimulation achieved an American College of Rheumatology 20% (ACR20) response at three months, compared to 24.2% in the sham group.

More importantly for long-term execution, the open-label extension of the trial showed that response rates climbed to 52.8% at 12 months, with approximately half of the patients achieving low disease activity or clinical remission. Furthermore, the therapy boasted a 98% persistence rate at one year—a stark contrast to the high dropout and switching rates commonly seen with traditional biologic drugs.

Forging a Cross-Specialty Ecosystem

The technological achievement of the SetPoint System is only half the battle. The operational challenge lies in rewiring the clinical pathways of the healthcare system itself.

Traditionally, a rheumatologist manages RA, and a neurosurgeon operates on the nervous system. The SetPoint System forces these two highly specialized silos to integrate. The procedures at UNM Hospital were performed by neurosurgeon Dr. James Botros, who previously served as a surgical investigator in the RESET-RA study. The patients, however, were diagnosed and referred by Dr. Hillary Norton, a rheumatologist and medical director at Inspire Santa Fe Medical Group.

"Treating rheumatoid arthritis has not traditionally been part of a neurosurgeon's practice, and that is what makes this therapy so different," said Dr. Botros following the procedures. "The vagus nerve plays an important role in regulating inflammation, and the SetPoint System allows us to engage that pathway directly. Having worked with this system since its clinical investigation, I look forward to seeing this collaboration with rheumatology continue to grow at UNM Hospital."

For rheumatologists, the device provides a much-needed alternative for a frustratingly refractory patient population. "Despite the number of advanced therapies available today, a significant group of my patients continue to live with active disease, side effects, or both," noted Dr. Norton. "The SetPoint System gives those patients a treatment that works through a different mechanism than anything they have tried before, and that is an important addition to how we treat RA."

However, independent healthcare analysts point out that scaling this collaboration nationally requires overcoming a steep educational curve. As one prominent bioelectronic medicine researcher observed, there remains a "deficit in declarative knowledge" among many practicing rheumatologists regarding neuroimmune biology. Building a seamless referral pipeline from the rheumatology clinic to the neurosurgery operating room is a logistical hurdle that SetPoint must navigate market by market.

The Economics of the Implant

In the world of medical disruption, clinical efficacy is meaningless without a viable economic model. Biologic therapies for RA represent massive recurring revenue streams for pharmaceutical companies, often costing tens of thousands of dollars per patient, per year, indefinitely.

The SetPoint System introduces a completely different economic equation: a single surgical implant with minimal ongoing maintenance costs. While this is theoretically attractive to payers looking to curb long-term specialty pharmacy spending, securing initial reimbursement for a novel device is notoriously difficult.

SetPoint Medical has executed a crucial strategic maneuver on this front. In late 2025, the Centers for Medicare & Medicaid Services (CMS) granted Transitional Pass-Through (TPT) payment status for the SetPoint System, which took effect on January 1, 2026. CMS also created a new device category code (C1607) in the Healthcare Common Procedure Coding System, acknowledging the device's novelty.

This TPT status provides incremental payment for the device in hospital outpatient and ambulatory surgery center settings for up to three years. It is a critical lifeline that allows hospitals like UNM to adopt the technology without absorbing massive financial losses while permanent reimbursement rates are established. While private commercial payers currently review coverage on a case-by-case basis requiring prior authorization, the Medicare TPT status serves as a powerful wedge to drive broader market adoption.

Moving from Pilot to Production

SetPoint Medical, backed by a $140 million funding round in 2025 that included industry heavyweights like Abbott and Boston Scientific, is not stopping at rheumatoid arthritis. The company is already moving to leverage its neurostimulation platform for other autoimmune conditions. A pilot clinical study evaluating the device for relapsing-remitting multiple sclerosis initiated enrollment in April 2026, and plans are underway for trials in Crohn's disease.

"Completing the first SetPoint System procedure in New Mexico adds another state to the growing list where SetPoint Therapy is available, and reflects our commitment to expanding access to neuroimmune modulation for people living with rheumatoid arthritis," said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical.

Yet, the reality of scaling a surgical intervention means acknowledging the risks. While the RESET-RA trial demonstrated a low 1.7% rate of related serious adverse events—mostly resolving in the perioperative period—the procedure carries surgical risks such as vocal cord paresis, prolonged hoarseness, and infection. It is contraindicated for patients with certain neck anatomies or those who cannot safely undergo anesthesia.

The expansion into New Mexico is a clear indicator that bioelectronic medicine is successfully transitioning from the laboratory to the commercial marketplace. The ultimate test for SetPoint Medical will not simply be the elegance of its technology, but its ability to execute on the ground—educating physicians, securing permanent payer coverage, and proving that a one-time surgical implant can reliably outperform a lifetime of pharmaceutical dependency.